A Caltech Library Service

Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering

Kelley, Shana O. and Mirkin, Chad A. and Walt, David R. and Ismagilov, Rustem F. and Toner, Mehmet and Sargent, Edward H. (2014) Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nature Nanotechnology, 9 (12). pp. 969-980. ISSN 1748-3387. PMCID PMC4472305. doi:10.1038/NNANO.2014.261.

[img] PDF - Accepted Version
See Usage Policy.


Use this Persistent URL to link to this item:


Rapid progress in identifying disease biomarkers has increased the importance of creating high-performance detection technologies. Over the last decade, the design of many detection platforms has focused on either the nano or micro length scale. Here, we review recent strategies that combine nano- and microscale materials and devices to produce large improvements in detection sensitivity, speed and accuracy, allowing previously undetectable biomarkers to be identified in clinical samples. Microsensors that incorporate nanoscale features can now rapidly detect disease-related nucleic acids expressed in patient samples. New microdevices that separate large clinical samples into nanocompartments allow precise quantitation of analytes, and microfluidic systems that utilize nanoscale binding events can detect rare cancer cells in the bloodstream more accurately than before. These advances will lead to faster and more reliable clinical diagnostic devices.

Item Type:Article
Related URLs:
URLURL TypeDescription ReadCube access CentralArticle
Kelley, Shana O.0000-0003-3360-5359
Mirkin, Chad A.0000-0002-6634-7627
Ismagilov, Rustem F.0000-0002-3680-4399
Sargent, Edward H.0000-0003-0396-6495
Additional Information:© 2014 Macmillan Publishers Limited. All rights reserved Received 9 March 2014; accepted 13 October 2014; published online 3 December 2014 S.O.K. and E.H.S. acknowledge Genome Canada, the Canadian Institute of Health Research, the Natural Sciences and Engineering Research Council, and the Ontario Research Fund for support of their work. M.T. acknowledges the National Institute of Health (NIH) P41 Resource Center, NIH National Institute of Biomedical Imaging and Bioengineering Quantum Grant. R.F.I acknowledges NIH grant R01EB012946 and the Defense Advanced Research Projects Agency (DARPA) Cooperative Agreement HR0011-11-2-0006 for support. D.R.W. acknowledges generous support from DARPA (HR0011-12-2,0001: SUB #5-55065) and a Department of Defense Innovator Award BC100510(W81XWH-11-1-0814). C.A.M. acknowledges support from the Center for Cancer Nanotechnology Excellence (CCNE) initiative of the National Institutes of Health (NIH), the Nanoscale Science and Engineering Centers (NSEC) initiative of the National Science Foundation, the Prostate Cancer Foundation, National Institute of Arthritis and Musculosketal and Skin Diseases/NIH, and DARPA. R.F.I. is a scientific founder, a Director, and has equity in SlipChip. D.R.W. is a scientific founder, a Director, and has equity in Quanterix. S.O.K. is a founder, a Director, and has equity in Xagenic. E.H.S. holds equity in Xagenic.
Funding AgencyGrant Number
Canadian Institutes of Health Research (CIHR)UNSPECIFIED
Natural Sciences and Engineering Research Council of Canada (NSERC)UNSPECIFIED
Ontario Research FundUNSPECIFIED
Defense Advanced Research Projects Agency (DARPA)HR0011-11-2-0006
Defense Advanced Research Projects Agency (DARPA)HR0011-12-2,0001: SUB #5-55065
Department of Defense Innovator AwardBC100510(W81XWH-11-1-0814)
Prostate Cancer FoundationUNSPECIFIED
Issue or Number:12
PubMed Central ID:PMC4472305
Record Number:CaltechAUTHORS:20141212-133134775
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:52770
Deposited By: SWORD User
Deposited On:22 Dec 2014 21:19
Last Modified:10 Nov 2021 19:43

Repository Staff Only: item control page